Search results
Showing 16 to 30 of 167 results for urinary tract infections
Four innovative tests for diagnosing UTIs could help in the fight against antimicrobial resistance
Innovative tests with the potential to help people with a urinary tract infection (UTI) receive the correct course of antibiotics more quickly could soon be considered for use in the NHS.
New NICE quality standard identifies improvements in UTI diagnosis for women
Health professionals should diagnose women under 65 with a urinary tract infection (UTI) if they have two or more key urinary symptoms according to a new quality standard published by NICE today (15 February 2023).
This quality standard covers diagnosing and managing urinary tract infections in adults aged 16 and over. It describes high-quality care in priority areas for improvement.
View quality statements for QS90Show all sections
Sections for QS90
- Quality statements
- Quality statement 1: Diagnosing urinary tract infections in women under 65
- Quality statement 2: Diagnosing urinary tract infections in adults with catheters
- Quality statement 3: Antibiotic treatment for asymptomatic bacteriuria in men and non-pregnant women
- Quality statement 4: Duration of antibiotic treatment for urinary tract infection
- Quality statement 5: Referring adults with recurrent urinary tract infection
- Update information
- About this quality standard
Evidence-based recommendations on Memokath 051 Ureter stent for ureteric obstruction.
View recommendations for MTG75Show all sections
Fostamatinib for treating refractory chronic immune thrombocytopenia (TA835)
Evidence-based recommendations on fostamatinib (Tavlesse) for chronic refractory chronic immune thrombocytopenia in adults.
iTind for lower urinary tract symptoms caused by benign prostatic hyperplasia (MIB306)
NICE has developed a medtech innovation briefing (MIB) on iTind for lower urinary tract symptoms caused by benign prostatic hyperplasia .
Evidence-based recommendations on prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia. This involves positioning a temporary implant in the urethra to increase the flow of urine.
View recommendations for IPG737Show all sections
Evidence-based recommendations on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections....
View recommendations for HTE1Show all sections
Cefiderocol for treating severe drug-resistant gram-negative bacterial infections (HTE2)
Evidence-based recommendations on cefiderocol for treating severe drug-resistant gram-negative bacterial infections....
conducted in the UK. Any explanatory notes(if applicable) Urinary tract infection and vesicoureteral reflux...
Source guidance details Comes from guidance Urinary tract infection in under 16s: diagnosis and management...
of urinary tract infection in children and young people aged 5 years and above but under 16 years: What are...
Source guidance details Comes from guidance Urinary tract infection in under 16s: diagnosis and management...
This quality standard covers diagnosing and managing urinary tract infection in infants, children and young people (under 16). It includes new and recurrent infections of the upper or lower urinary tract. It describes high-quality care in priority areas for improvement.
View quality statements for QS36Show all sections
Sections for QS36
- Quality statements
- Quality statement 1: Presentation with unexplained fever of 38°C or higher
- Quality statement 2: History and examination – recording of risk factors
- Quality statement 3: Laboratory reporting – differentiation of E. coli and non-E. coli organisms
- Quality statement 4: Information about recognising re-infection
- Update information
- About this quality standard
Urinary tract infection in under 16s: diagnosis and management (NG224)
This guideline covers diagnosing and managing first or recurrent upper or lower urinary tract infection (UTI) in babies, children and young people under 16. It aims to achieve more consistent clinical practice, based on accurate diagnosis and effective management. It does not cover babies, children and young people with urinary catheters in situ, neurogenic bladders, significant pre-existing urinary tract disorders (uropathies), underlying renal disease or immunosuppression, or recurrent UTI in sexually active girls and young women under 16. It also does not cover babies, children and young people in intensive care units.